Mapping the G-structures and supersymmetric vacua of five-dimensional N=4 supergravity

We classify the supersymmetric vacua of N=4, d=5 supergravity in terms of G-structures. We identify three classes of solutions: with R^3, SU(2) and generic SO(4) structure. Using the Killing spinor equations, we fully characterize the first two classes and partially solve the latter. With the N=4 graviton multiplet decomposed in terms of N=2 multiplets: the graviton, vector and gravitino multiplets, we obtain new supersymmetric solutions corresponding to turning on fields in the gravitino multiplet. These vacua are described in terms of an SO(5) vector sigma-model coupled with gravity, in three or four dimensions. A new feature of these N=4 vacua, which is not seen from an N=2 point of view, is the possibility for preserving more exotic fractions of supersymmetry. We give a few concrete examples of these new supersymmetric (albeit singular) solutions. Additionally, we show how by truncating the N=4, d=5 set of fields to minimal supergravity coupled with one vector multiplet we recover the known two-charge solutions.Comment: 31 pages, late

Decoherence and the rate of entropy production in chaotic quantum systems

We show that for an open quantum system which is classically chaotic (a quartic double well with harmonic driving coupled to a sea of harmonic oscillators) the rate of entropy production has, as a function of time, two relevant regimes: For short times it is proportional to the diffusion coefficient (fixed by the system--environment coupling strength). For longer times (but before equilibration) there is a regime where the entropy production rate is fixed by the Lyapunov exponent. The nature of the transition time between both regimes is investigated.Comment: Revtex, 4 pages, 3 figures include

The Effects of Fertilization and Water Management on Growth and Production of Nile Tilapia in Deep Ponds During the Dry Season

Fertilization guidelines developed for shallow ponds (1 m) with controlled depths were tested in deeper (2.5 m) ponds to determine effectiveness of these guidelines for culture of Nile tilapia Oreochromis niloticus . Twelve ponds of 2.5-m depth were used in four treatments: (A) weekly fertilization with water addition; (B) weekly fertilization without water addition; (C) one early fertilization without water addition; and (D) fertilization frequency dependent on nutrient concentrations, without water addition. Sex-reversed Nile tilapia were stocked at 2 fish/m 2 with an initial weight of 15 g, and harvested after 234 d. Depth of water declined from 2.4 m to 1.6 m over the experiment in ponds without water addition. Fish growth rate was significantly higher in treatments A and B (0.86 g/d), than in other treatments, as was yield (3,830 kg/ha). Treatment C was lowest in growth (0.086 g/d) and yield (168 kg/ha), with treatment D intermediate. Fish growth rates and yields were strongly correlated to manure input ( R 2 = 0.89 and 0.94, respectively), and residuals were not correlated to any physical or chemical variables. Growth and yield in these deep ponds were somewhat lower than those in previous experiments for shallow ponds with regular water inputs. However, stagnant ponds did not accumulate nutrients and metabolites at rates higher than ponds with controlled water depths.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/73615/1/j.1749-7345.1998.tb00664.x.pd

MCT1 in Invasive Ductal Carcinoma: Monocarboxylate Metabolism and Aggressive Breast Cancer.

Introduction: Monocarboxylate transporter 1 (MCT1) is an importer of monocarboxylates such as lactate and pyruvate and a marker of mitochondrial metabolism. MCT1 is highly expressed in a subgroup of cancer cells to allow for catabolite uptake from the tumor microenvironment to support mitochondrial metabolism. We studied the protein expression of MCT1 in a broad group of breast invasive ductal carcinoma specimens to determine its association with breast cancer subtypes and outcomes. Methods: MCT1 expression was evaluated by immunohistochemistry on tissue micro-arrays (TMA) obtained through our tumor bank. Two hundred and fifty-seven cases were analyzed: 180 cases were estrogen receptor and/or progesterone receptor positive (ER+ and/or PR+), 62 cases were human epidermal growth factor receptor 2 positive (HER2+), and 56 cases were triple negative breast cancers (TNBC). MCT1 expression was quantified by digital pathology with Aperio software. The intensity of the staining was measured on a continuous scale (0-black to 255-bright white) using a co-localization algorithm. Statistical analysis was performed using a linear mixed model. Results: High MCT1 expression was more commonly found in TNBC compared to ER+ and/or PR+ and compared to HER-2+ (p \u3c 0.001). Tumors with an in-situ component were less likely to stain strongly for MCT1 (p \u3c 0.05). High nuclear grade was associated with higher MCT1 staining (p \u3c 0.01). Higher T stage tumors were noted to have a higher expression of MCT1 (p \u3c 0.05). High MCT1 staining in cancer cells was associated with shorter progression free survival, increased risk of recurrence, and larger size independent of TNBC status (p \u3c 0.05). Conclusion: MCT1 expression, which is a marker of high catabolite uptake and mitochondrial metabolism, is associated with recurrence in breast invasive ductal carcinoma. MCT1 expression as quantified with digital image analysis may be useful as a prognostic biomarker and to design clinical trials using MCT1 inhibitors

Msh2 ATPase Activity Is Essential for Somatic Hypermutation at A-T Basepairs and for Efficient Class Switch Recombination

Somatic hypermutation (SHM) and class switch recombination (CSR) are initiated by activation-induced cytidine deaminase–mediated cytidine deamination of immunoglobulin genes. MutS homologue (Msh) 2−/− mice have reduced A-T mutations and CSR. This suggests that Msh2 may play a role in repairing activation-induced cytidine deaminase–generated G-U mismatches. However, because Msh2 not only initiates mismatch repair but also has other functions, such as signaling for apoptosis, it is not known which activity of Msh2 is responsible for the effects observed, and consequently, many models have been proposed. To further dissect the role of Msh2 in SHM and CSR, mice with a “knockin” mutation in the Msh2 gene that inactivates the adenosine triphosphatase domain were examined. This mutation (i.e., Msh2G674A), which does not affect apoptosis signaling, allows mismatches to be recognized but prevents Msh2 from initiating mismatch repair. Here, we show that, similar to Msh2−/− mice, SHM in Msh2G674A mice is biased toward G-C mutations. However, CSR is partially reduced, and switch junctions are more similar to those of postmeiotic segregation 2−/− mice than to Msh2−/− mice. These results indicate that Msh2 adenosine triphosphatase activity is required for A-T mutations, and suggest that Msh2 has more than one role in CSR

Quantum effects after decoherence in a quenched phase transition

We study a quantum mechanical toy model that mimics some features of a quenched phase transition. Both by virtue of a time-dependent Hamiltonian or by changing the temperature of the bath we are able to show that even after classicalization has been reached, the system may display quantum behaviour again. We explain this behaviour in terms of simple non-linear analysis and estimate relevant time scales that match the results of numerical simulations of the master-equation. This opens new possibilities both in the study of quantum effects in non-equilibrium phase transitions and in general time-dependent problems where quantum effects may be relevant even after decoherence has been completed.Comment: 7 pages, 7 figures, revtex, important revisions made. To be published in Phys. Rev.

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection.

Currently, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated interferon plus ribavirin. In an open-label study, we evaluated the safety and efficacy of sofosbuvir plus ribavirin for 12 weeks in children aged 3 to <12 years chronically infected with genotype 2 or for 24 weeks in patients with genotype 3. Patients aged 3 to <6 years weighing <17 kg received sofosbuvir 150 mg, and patients aged 3 to <6 years weighing ≥17 kg and all patients aged 6 to <12 years received sofosbuvir 200 mg once daily. Intensive pharmacokinetic sampling conducted in each age group confirmed the appropriateness of sofosbuvir doses. For all patients, ribavirin dosing was determined by baseline weight (up to 1,400 mg/day, two divided doses). The primary efficacy endpoint was sustained virologic response 12 weeks after therapy (SVR12). Fifty-four patients were enrolled (41 aged 6 to <12 years and 13 aged 3 to <6 years). Most were treatment naïve (98%) and infected perinatally (94%). All but one patient achieved SVR12 (53/54, 98%; 95% confidence interval, 90%-100%). The patient who did not achieve SVR12 was a 4-year-old who discontinued treatment after 3 days because of "abnormal drug taste." The most commonly reported adverse events in patients aged 6 to <12 years were vomiting (32%) and headache (29%), and those in patients aged 3 to <6 years were vomiting (46%) and diarrhea (39%). One 3-year-old patient had a serious adverse event of accidental ribavirin overdose requiring hospitalization for monitoring; this patient completed treatment and achieved SVR12. Conclusion: Sofosbuvir plus ribavirin was well tolerated and highly effective in children aged 3 to <12 years with chronic HCV genotype 2 or 3 infection

Sexual Satisfaction and the Importance of Sexual Health to Quality of Life Throughout the Life Course of U.S. Adults

Discussions about sexual health are uncommon in clinical encounters, despite the sexual dysfunction associated with many common health conditions. Understanding of the importance of sexual health and sexual satisfaction among US adults is limited

A Transient Sub-Eddington Black Hole X-ray Binary Candidate in the Dust Lanes of Centaurus A

We report the discovery of a bright X-ray transient, CXOU J132527.6-430023, in the nearby early-type galaxy NGC 5128. The source was first detected over the course of five Chandra observations in 2007, reaching an unabsorbed outburst luminosity of 1-2*10^38 erg/s in the 0.5-7.0 keV band before returning to quiescence. Such luminosities are possible for both stellar-mass black hole and neutron star X-ray binary transients. Here, we attempt to characterize the nature of the compact object. No counterpart has been detected in the optical or radio sky, but the proximity of the source to the dust lanes allows for the possibility of an obscured companion. The brightness of the source after a >100 fold increase in X-ray flux makes it either the first confirmed transient non-ULX black hole system in outburst to be subject to detailed spectral modeling outside the Local Group, or a bright (>10^38 erg/s) transient neutron star X-ray binary, which are very rare. Such a large increase in flux would appear to lend weight to the view that this is a black hole transient. X-ray spectral fitting of an absorbed power law yielded unphysical photon indices, while the parameters of the best-fit absorbed disc blackbody model are typical of an accreting ~10 Msol black hole in the thermally dominant state.Comment: 8 pages, 6 figures, accepted for publication in Ap

Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss

Abstract: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative condition that primarily affects the motor system and shares many features with frontotemporal dementia (FTD). Evidence suggests that ALS is a ‘dying-back’ disease, with peripheral denervation and axonal degeneration occurring before loss of motor neuron cell bodies. Distal to a nerve injury, a similar pattern of axonal degeneration can be seen, which is mediated by an active axon destruction mechanism called Wallerian degeneration. Sterile alpha and TIR motif-containing 1 (Sarm1) is a key gene in the Wallerian pathway and its deletion provides long-term protection against both Wallerian degeneration and Wallerian-like, non-injury induced axonopathy, a retrograde degenerative process that occurs in many neurodegenerative diseases where axonal transport is impaired. Here, we explored whether Sarm1 signalling could be a therapeutic target for ALS by deleting Sarm1 from a mouse model of ALS-FTD, a TDP-43Q331K, YFP-H double transgenic mouse. Sarm1 deletion attenuated motor axon degeneration and neuromuscular junction denervation. Motor neuron cell bodies were also significantly protected. Deletion of Sarm1 also attenuated loss of layer V pyramidal neuronal dendritic spines in the primary motor cortex. Structural MRI identified the entorhinal cortex as the most significantly atrophic region, and histological studies confirmed a greater loss of neurons in the entorhinal cortex than in the motor cortex, suggesting a prominent FTD-like pattern of neurodegeneration in this transgenic mouse model. Despite the reduction in neuronal degeneration, Sarm1 deletion did not attenuate age-related behavioural deficits caused by TDP-43Q331K. However, Sarm1 deletion was associated with a significant increase in the viability of male TDP-43Q331K mice, suggesting a detrimental role of Wallerian-like pathways in the earliest stages of TDP-43Q331K-mediated neurodegeneration. Collectively, these results indicate that anti-SARM1 strategies have therapeutic potential in ALS-FTD